Literature DB >> 30237154

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.

Christoph Driessen1, Rouven Müller2, Urban Novak3, Nathan Cantoni4, Daniel Betticher5, Nicolas Mach6, Axel Rüfer7, Ulrich Mey8, Panagiotis Samaras9, Karin Ribi10, Lenka Besse1, Andrej Besse1, Catherine Berset11, Stephanie Rondeau11, Hanne Hawle11, Felicitas Hitz1, Thomas Pabst3, Thilo Zander12.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30237154      PMCID： PMC6238158          DOI： 10.1182/blood-2018-05-851170

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  19 in total

1.  Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.

Authors:  Chungyee Leung-Hagesteijn; Natalie Erdmann; Grace Cheung; Jonathan J Keats; A Keith Stewart; Donna E Reece; Kim Chan Chung; Rodger E Tiedemann
Journal:  Cancer Cell       Date:  2013-09-09       Impact factor: 31.743

Review 2.  Proteolysis: from the lysosome to ubiquitin and the proteasome.

Authors:  Aaron Ciechanover
Journal:  Nat Rev Mol Cell Biol       Date:  2005-01       Impact factor: 94.444

3.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Authors:  S Vincent Rajkumar; Jean-Luc Harousseau; Brian Durie; Kenneth C Anderson; Meletios Dimopoulos; Robert Kyle; Joan Blade; Paul Richardson; Robert Orlowski; David Siegel; Sundar Jagannath; Thierry Facon; Hervé Avet-Loiseau; Sagar Lonial; Antonio Palumbo; Jeffrey Zonder; Heinz Ludwig; David Vesole; Orhan Sezer; Nikhil C Munshi; Jesus San Miguel
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

4.  Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.

Authors:  Jatin J Shah; Edward A Stadtmauer; Rafat Abonour; Adam D Cohen; William I Bensinger; Cristina Gasparetto; Jonathan L Kaufman; Suzanne Lentzsch; Dan T Vogl; Christina L Gomes; Natalia Pascucci; David D Smith; Robert Z Orlowski; Brian G M Durie
Journal:  Blood       Date:  2015-09-17       Impact factor: 22.113

5.  Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).

Authors:  Christoph Driessen; Marianne Kraus; Markus Joerger; Hilde Rosing; Jürgen Bader; Felicitas Hitz; Catherine Berset; Alexandros Xyrafas; Hanne Hawle; Gregoire Berthod; Hermann S Overkleeft; Christiana Sessa; Alwin Huitema; Thomas Pabst; Roger von Moos; Dagmar Hess; Ulrich J M Mey
Journal:  Haematologica       Date:  2015-12-11       Impact factor: 9.941

6.  Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

Authors:  Paul G Richardson; David S Siegel; Ravi Vij; Craig C Hofmeister; Rachid Baz; Sundar Jagannath; Christine Chen; Sagar Lonial; Andrzej Jakubowiak; Nizar Bahlis; Kevin Song; Andrew Belch; Noopur Raje; Chaim Shustik; Suzanne Lentzsch; Martha Lacy; Joseph Mikhael; Jeffrey Matous; David Vesole; Min Chen; Mohamed H Zaki; Christian Jacques; Zhinuan Yu; Kenneth C Anderson
Journal:  Blood       Date:  2014-01-13       Impact factor: 22.113

7.  A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Authors:  David S Siegel; Thomas Martin; Michael Wang; Ravi Vij; Andrzej J Jakubowiak; Sagar Lonial; Suzanne Trudel; Vishal Kukreti; Nizar Bahlis; Melissa Alsina; Asher Chanan-Khan; Francis Buadi; Frederic J Reu; George Somlo; Jeffrey Zonder; Kevin Song; A Keith Stewart; Edward Stadtmauer; Lori Kunkel; Sandra Wear; Alvin F Wong; Robert Z Orlowski; Sundar Jagannath
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

8.  Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.

Authors:  Meletios A Dimopoulos; Antonio Palumbo; Paolo Corradini; Michele Cavo; Michel Delforge; Francesco Di Raimondo; Katja C Weisel; Albert Oriol; Markus Hansson; Angelo Vacca; María Jesús Blanchard; Hartmut Goldschmidt; Chantal Doyen; Martin Kaiser; Mario Petrini; Pekka Anttila; Anna Maria Cafro; Reinier Raymakers; Jesus San-Miguel; Felipe de Arriba; Stefan Knop; Christoph Röllig; Enrique M Ocio; Gareth Morgan; Neil Miller; Mathew Simcock; Teresa Peluso; Jennifer Herring; Lars Sternas; Mohamed H Zaki; Philippe Moreau
Journal:  Blood       Date:  2016-05-25       Impact factor: 22.113

9.  Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance.

Authors:  M Kraus; J Bader; H Overkleeft; C Driessen
Journal:  Blood Cancer J       Date:  2013-03-01       Impact factor: 11.037

10.  Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism.

Authors:  G P Soriano; L Besse; N Li; M Kraus; A Besse; N Meeuwenoord; J Bader; B Everts; H den Dulk; H S Overkleeft; B I Florea; C Driessen
Journal:  Leukemia       Date:  2016-04-27       Impact factor: 11.528
View more
  14 in total

1.  Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma.

Authors:  Nitya Nathwani; Joycelynne Palmer; Timothy W Synold; Behrouz Salehian; Michael Rosenzweig; James F Sanchez; Samantha N Hammond; Kehinde Adekola; Valeria Tomarchio; Arnab Chowdhury; Chatchada Karanes; Myo Htut; Firoozeh Sahebi; Tanya Siddiqi; Amrita Krishnan; Stephen J Forman; Steven T Rosen
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-05-29

2.  Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.

Authors:  Nizar J Bahlis; Heather Sutherland; Darrell White; Michael Sebag; Suzanne Lentzsch; Rami Kotb; Christopher P Venner; Cristina Gasparetto; Aldo Del Col; Paola Neri; Donna Reece; Michael Kauffman; Sharon Shacham; T J Unger; Jacqueline Jeha; Jean-Richard Saint-Martin; Jatin Shah; Christine Chen
Journal:  Blood       Date:  2018-10-23       Impact factor: 22.113

3.  Mammalian Ddi2 is a shuttling factor containing a retroviral protease domain that influences binding of ubiquitylated proteins and proteasomal degradation.

Authors:  Galen Andrew Collins; Zhe Sha; Chueh-Ling Kuo; Beyza Erbil; Alfred L Goldberg
Journal:  J Biol Chem       Date:  2022-03-28       Impact factor: 5.486

Review 4.  The Impact of Matrix Metalloproteinase-9 on the Sequential Steps of the Metastatic Process.

Authors:  Giovanni Barillari
Journal:  Int J Mol Sci       Date:  2020-06-25       Impact factor: 5.923

Review 5.  The Anti-Angiogenic Effects of Anti-Human Immunodeficiency Virus Drugs.

Authors:  Giovanni Barillari
Journal:  Front Oncol       Date:  2020-05-21       Impact factor: 6.244

6.  Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10).

Authors:  F Hitz; M Kraus; T Pabst; D Hess; L Besse; T Silzle; U Novak; K Seipel; S Rondeau; S Stüdeli; S Berardi Vilei; P Samaras; U Mey; C Driessen
Journal:  Blood Cancer J       Date:  2019-08-27       Impact factor: 11.037

7.  Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma.

Authors:  Dominika Fassmannová; František Sedlák; Jindřich Sedláček; Ivan Špička; Klára Grantz Šašková
Journal:  Cancers (Basel)       Date:  2020-04-25       Impact factor: 6.639

8.  Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival.

Authors:  Tianzeng Chen; Matthew Ho; Jenna Briere; Maria Moscvin; Peter G Czarnecki; Kenneth C Anderson; T Keith Blackwell; Giada Bianchi
Journal:  Blood Adv       Date:  2022-01-25

Review 9.  Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.

Authors:  Huanjie Yang; Xin Chen; Kai Li; Hassan Cheaito; Qianqian Yang; Guojun Wu; Jinbao Liu; Q Ping Dou
Journal:  Semin Cancer Biol       Date:  2019-12-26       Impact factor: 15.707

10.  Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma.

Authors:  Lenka Besse; Andrej Besse; Sara C Stolze; Amin Sobh; Esther A Zaal; Alwin J van der Ham; Mario Ruiz; Santosh Phuyal; Lorina Büchler; Marc Sathianathan; Bogdan I Florea; Jan Borén; Marcus Ståhlman; Julia Huber; Arnold Bolomsky; Heinz Ludwig; J Thomas Hannich; Alex Loguinov; Bart Everts; Celia R Berkers; Marc Pilon; Hesso Farhan; Christopher D Vulpe; Herman S Overkleeft; Christoph Driessen
Journal:  Cancer Res       Date:  2021-06-22       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.